APA

Goodkin D. E., Rudick R. A., VanderBrug Medendorp S., Greene T., Schwetz K. M., Fischer J., Daughtry M. M., Ross J. & Van Dyke C. (19940317). Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis. Design of a randomized, placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data on toxicity. : The Online journal of current clinical trials.

Chicago

Goodkin D E, Rudick R A, VanderBrug Medendorp S, Greene T, Schwetz K M, Fischer J, Daughtry M M, Ross J and Van Dyke C. 19940317. Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis. Design of a randomized, placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data on toxicity. : The Online journal of current clinical trials.

Harvard

Goodkin D. E., Rudick R. A., VanderBrug Medendorp S., Greene T., Schwetz K. M., Fischer J., Daughtry M. M., Ross J. and Van Dyke C. (19940317). Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis. Design of a randomized, placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data on toxicity. : The Online journal of current clinical trials.

MLA

Goodkin D E, Rudick R A, VanderBrug Medendorp S, Greene T, Schwetz K M, Fischer J, Daughtry M M, Ross J and Van Dyke C. Low-dose (7.5 mg) oral methotrexate for chronic progressive multiple sclerosis. Design of a randomized, placebo-controlled trial with sample size benefits from a composite outcome variable including preliminary data on toxicity. : The Online journal of current clinical trials. 19940317.